Compare Stocks: TELO, QTTB, ABEO, and UPB

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABEO Abeona Therapeutics	$5.41 -1.3%	$6.40	$4.00 ▼ $7.65	$309.65M	1.33	1.30 million shs	1.60 million shs
QTTB Q32 Bio	$11.10 +3.5%	$14.86	$1.69 ▼ $23.57	$330.44M	0.21	429,383 shs	1.82 million shs
TELO Telomir Pharmaceuticals	$1.17 -0.8%	$1.16	$0.89 ▼ $2.09	$80.47M	-0.25	49,228 shs	33,075 shs
UPB Upstream Bio	$5.73 -0.3%	$6.81	$5.65 ▼ $33.68	$313.84M	1.28	601,672 shs	501,307 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABEO Abeona Therapeutics	-1.28%	-9.83%	-27.48%	-2.17%	-17.15%
QTTB Q32 Bio	+3.54%	-7.42%	-27.78%	-12.18%	+523.60%
TELO Telomir Pharmaceuticals	-0.85%	+0.86%	+5.41%	-7.14%	-7.14%
UPB Upstream Bio	-0.35%	-4.66%	-17.08%	-6.07%	-67.81%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABEO Abeona Therapeutics	$5.41 -1.3%	$6.40	$4.00 ▼ $7.65	$309.65M	1.33	1.30 million shs	1.60 million shs
QTTB Q32 Bio	$11.10 +3.5%	$14.86	$1.69 ▼ $23.57	$330.44M	0.21	429,383 shs	1.82 million shs
TELO Telomir Pharmaceuticals	$1.17 -0.8%	$1.16	$0.89 ▼ $2.09	$80.47M	-0.25	49,228 shs	33,075 shs
UPB Upstream Bio	$5.73 -0.3%	$6.81	$5.65 ▼ $33.68	$313.84M	1.28	601,672 shs	501,307 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABEO Abeona Therapeutics	-1.28%	-9.83%	-27.48%	-2.17%	-17.15%
QTTB Q32 Bio	+3.54%	-7.42%	-27.78%	-12.18%	+523.60%
TELO Telomir Pharmaceuticals	-0.85%	+0.86%	+5.41%	-7.14%	-7.14%
UPB Upstream Bio	-0.35%	-4.66%	-17.08%	-6.07%	-67.81%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABEO Abeona Therapeutics	2.33	Hold	$19.33	257.36% Upside
QTTB Q32 Bio	2.86	Moderate Buy	$31.00	179.28% Upside
TELO Telomir Pharmaceuticals	2.00	Hold	N/A	N/A
UPB Upstream Bio	2.43	Hold	$29.67	417.74% Upside

Current Analyst Ratings Breakdown

Latest TELO, QTTB, ABEO, and UPB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/7/2026	QTTB Q32 Bio	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
9/2/2026	UPB Upstream Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$36.00
8/24/2026	QTTB Q32 Bio	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$34.00
8/21/2026	QTTB Q32 Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C)
8/17/2026	ABEO Abeona Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (D)
8/17/2026	UPB Upstream Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/14/2026	ABEO Abeona Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$22.00 ➝ $21.00
8/14/2026	UPB Upstream Bio	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$8.00 ➝ $9.00
8/11/2026	UPB Upstream Bio	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$25.00
8/7/2026	QTTB Q32 Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C-)
8/3/2026	ABEO Abeona Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C-) ➝ Sell (D+)

(Data available from 9/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABEO Abeona Therapeutics	$5.82M	53.15	N/A	N/A	$2.94 per share	1.84
QTTB Q32 Bio	$53.74M	6.15	$1.57 per share	7.07	$3.41 per share	3.26
TELO Telomir Pharmaceuticals	N/A	N/A	N/A	N/A	$0.17 per share	N/A
UPB Upstream Bio	$3.16M	99.38	N/A	N/A	$6.29 per share	0.91

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABEO Abeona Therapeutics	$71.18M	-$1.09	N/A	N/A	N/A	N/A	-41.69%	-30.36%	11/11/2026 (Estimated)
QTTB Q32 Bio	$29.82M	$3.00	3.70	N/A	N/A	N/A	50.17%	29.49%	11/12/2026 (Estimated)
TELO Telomir Pharmaceuticals	-$10.41M	-$0.91	N/A	N/A	N/A	N/A	-102.70%	-90.75%	N/A
UPB Upstream Bio	-$143.44M	-$2.90	N/A	N/A	N/A	-4,955.67%	-48.40%	-46.57%	11/4/2026 (Estimated)

Latest TELO, QTTB, ABEO, and UPB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	ABEO Abeona Therapeutics	-$0.2317	-$0.35	-$0.1183	-$0.35	$12.24 million	$11.38 million
8/13/2026	Q2 2026	TELO Telomir Pharmaceuticals	-$0.07	-$0.79	-$0.72	-$0.79	N/A	N/A
8/11/2026	Q2 2026	UPB Upstream Bio	-$0.7444	-$0.73	+$0.0144	-$0.73	$0.56 million	$0.77 million
8/5/2026	Q2 2026	QTTB Q32 Bio	-$0.46	-$0.44	+$0.02	-$0.44	$0.75 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABEO Abeona Therapeutics	N/A	N/A	N/A	N/A	N/A
QTTB Q32 Bio	N/A	N/A	N/A	N/A	N/A
TELO Telomir Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
UPB Upstream Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABEO Abeona Therapeutics	0.01	6.63	6.40
QTTB Q32 Bio	N/A	20.30	20.30
TELO Telomir Pharmaceuticals	N/A	16.16	16.16
UPB Upstream Bio	N/A	27.99	27.99

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABEO Abeona Therapeutics	80.56%
QTTB Q32 Bio	31.32%
TELO Telomir Pharmaceuticals	N/A
UPB Upstream Bio	N/A

Insider Ownership

Company	Insider Ownership
ABEO Abeona Therapeutics	7.10%
QTTB Q32 Bio	34.46%
TELO Telomir Pharmaceuticals	16.36%
UPB Upstream Bio	16.46%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABEO Abeona Therapeutics	90	57.18 million	53.12 million	Optionable
QTTB Q32 Bio	39	29.77 million	19.51 million	N/A
TELO Telomir Pharmaceuticals	1	68.78 million	57.52 million	N/A
UPB Upstream Bio	38	54.77 million	45.76 million	N/A

TELO, QTTB, ABEO, and UPB Headlines

Recent News About These Companies

Upstream Bio Reports Phase 2 VALIANT Trial Results Showing Verekitug Reduced Severe Asthma Exacerbations by 56% with Quarterly Dosing

September 8, 2026 | quiverquant.comQ

Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026

September 8, 2026 | globenewswire.com

HC Wainwright Forecasts Reduced Earnings for Upstream Bio

September 6, 2026 | americanbankingnews.com

FY2028 EPS Estimates for Upstream Bio Decreased by Analyst

September 4, 2026 | marketbeat.com

HC Wainwright Reaffirms "Buy" Rating for Upstream Bio (NASDAQ:UPB)

September 4, 2026 | americanbankingnews.com

BlackRock Inc. Purchases New Holdings in Upstream Bio, Inc. $UPB

September 3, 2026 | marketbeat.com

Analysts Are Bullish on These NA Stocks: Upstream Bio, Inc. (UPB), Fervo Energy Company Class A (FRVO)

September 2, 2026 | theglobeandmail.com

Upstream Bio (NASDAQ:UPB) Receives Buy Rating from HC Wainwright

September 2, 2026 | marketbeat.com

Upstream Bio on Track to Begin Two Phase 3 Verekitug Trials in Q1 2027

September 1, 2026 | finance.yahoo.com

Upstream Bio Outlines Phase 3 Plans for Verekitug

September 1, 2026 | tipranks.com

Upstream Bio Announces Pivotal Phase 3 Development Plans for Verekitug in Both Severe Asthma and CRSwNP

September 1, 2026 | globenewswire.com

Deutsche Bank AG Buys New Shares in Upstream Bio, Inc. $UPB

August 29, 2026 | marketbeat.com

Parkman Healthcare Partners LLC Makes New $6.47 Million Investment in Upstream Bio, Inc. $UPB

August 25, 2026 | marketbeat.com

Upstream Bio, Inc. (NASDAQ:UPB) Given Consensus Recommendation of "Hold" by Analysts

August 25, 2026 | marketbeat.com

Upstream Bio Inc (UPB)

August 16, 2026 | investing.com

Walleye Capital LLC Invests $3.45 Million in Upstream Bio, Inc. $UPB

August 15, 2026 | marketbeat.com

Upstream Bio (NASDAQ:UPB) Lowered to "Strong Sell" Rating by Wall Street Zen

August 15, 2026 | marketbeat.com

Upstream Bio (NASDAQ:UPB) Given New $9.00 Price Target at JPMorgan Chase & Co.

August 14, 2026 | marketbeat.com

Q3 EPS Estimates for Upstream Bio Decreased by HC Wainwright

August 14, 2026 | marketbeat.com

Upstream Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Progress

August 11, 2026 | markets.businessinsider.com

Upstream Bio, Inc. (UPB) Reports Q2 Loss, Tops Revenue Estimates

August 11, 2026 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TELO, QTTB, ABEO, and UPB Company Descriptions

Abeona Therapeutics NASDAQ:ABEO

$5.41 -0.07 (-1.28%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$5.56 +0.16 (+2.87%)

As of 09/11/2026 07:30 PM Eastern

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.

Q32 Bio NASDAQ:QTTB

$11.10 +0.38 (+3.54%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$11.10 +0.01 (+0.05%)

As of 09/11/2026 07:30 PM Eastern

Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.

Telomir Pharmaceuticals NASDAQ:TELO

$1.17 -0.01 (-0.85%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$1.19 +0.02 (+1.37%)

As of 09/11/2026 07:57 PM Eastern

Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.

Upstream Bio NASDAQ:UPB

$5.73 -0.02 (-0.35%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$5.72 -0.01 (-0.09%)

As of 09/11/2026 07:30 PM Eastern

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TELO, QTTB, ABEO, and UPB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TELO, QTTB, ABEO, and UPB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TELO, QTTB, ABEO, and UPB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TELO, QTTB, ABEO, and UPB Company Descriptions

Abeona Therapeutics NASDAQ:ABEO

Q32 Bio NASDAQ:QTTB

Telomir Pharmaceuticals NASDAQ:TELO

Upstream Bio NASDAQ:UPB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TELO, QTTB, ABEO, and UPB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TELO, QTTB, ABEO, and UPB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TELO, QTTB, ABEO, and UPB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TELO, QTTB, ABEO, and UPB Company Descriptions

Abeona Therapeutics NASDAQ:ABEO

Q32 Bio NASDAQ:QTTB

Telomir Pharmaceuticals NASDAQ:TELO

Upstream Bio NASDAQ:UPB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools